Provided by Tiger Fintech (Singapore) Pte. Ltd.

Evaxion Biotech A/S

3.13
+0.550021.32%
Post-market: 2.95-0.1800-5.75%19:25 EDT
Volume:418.78K
Turnover:1.26M
Market Cap:19.77M
PE:-0.52
High:3.18
Open:2.80
Low:2.80
Close:2.58
Loading ...

European Equities Traded in the US as American Depositary Receipts Advance Friday

MT Newswires Live
·
06 Jun

European Equities Traded in the US as American Depositary Receipts Rise Thursday

MT Newswires Live
·
05 Jun

Evaxion Receives Grant Funding to Design New Polio Vaccine

THOMSON REUTERS
·
03 Jun

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
02 Jun

European Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Trading

MT Newswires Live
·
29 May

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading

MT Newswires Live
·
28 May

Evaxion Biotech: Promising Pipeline and Strategic Collaborations Drive Buy Rating

TIPRANKS
·
28 May

Evaxion A/S reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
27 May

Evaxion A/S Reports Q1 2025 Progress and Financial Results

TIPRANKS
·
27 May

Evaxion A/S Reports Q1 2025 Financial Results: Revenue at $0, Net Loss of $1,580K, EPS at $(0.01)

Reuters
·
27 May

Evaxion Biotech Q1 GAAP EPS $(0.01) Beats $(0.65) Estimate

Benzinga
·
27 May

BRIEF-Evaxion Biotech Q1 Basic EPS USD -0.01

Reuters
·
27 May

Evaxion Announces Business Update and First Quarter 2025 Financial Results

THOMSON REUTERS
·
27 May

Evaxion Biotech Q1 Pretax Profit USD -1.772 Million

THOMSON REUTERS
·
27 May

Evaxion a/S - Current Cash at Hand Sufficient to Fund Operations Until Mid-2026

THOMSON REUTERS
·
27 May

Evaxion A/S expected to post a loss of 65 cents a share - Earnings Preview

Reuters
·
23 May

European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading

MT Newswires Live
·
22 May

Evaxion Begins Extension of Phase 2 Trial for AI-Designed Cancer Vaccine

TIPRANKS
·
22 May

Evaxion Biotech Doses First Patient in Extension of Cancer Vaccine Trial

MT Newswires Live
·
22 May

BRIEF-Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Reuters
·
22 May